Voluntary Announcement Patient Enrollment Completed for the Phase III Clinical Study of BA5101 in China

Boan Biotech Will Presents Results of Phase 3 Clinical Study for Denosumab Injection (BA1102) Conducted in China at the 2023 ASCO Annual Meeting

Boan Biotech recently announced that the results of phase 3 clinical study for its in-house developed Denosumab Injection (BA1102), a biosimilar product for oncology indications, will presented at the...

Supplemental Notice of Annual General Meeting

First Subject Enrolled in Boan Biotech’s International Multi-Center Phase 3 Clinical Study for Its Denosumab BA6101 & BA1102

Yantai, China, May 4, 2023 – Boan Biotech today announced that an international multi-center Phase 3 clinical study for its in-house developed Denosumab Injection (BA6101; BA1102) has been initi...

Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2023

Voluntary Announcement First Subject Enrolled in International Multi-Center Phase 3 Clinical Study of Denosumab

Boan Biotech Releases Its First ESG Report, Shouldering ESG Responsibilities and Pursuing High-quality Development

Recently, Boan Biotech published its first Environmental, Social and Governance Report (“ESG Report”). Responding to internal and external stakeholders’ focuses and concerns on company develop...

Form of Proxy for Use at Annual General Meeting to be Held on 29 May 2023 (Applicable to Holders of H Shares)

Notice of Annual General Meeting

(1) 2022 Report of the Board of Directors (2) 2022 Report of the Board of Supervisors (3) 2022 Annual Report (4) Re-Appointment of Auditor (5) Remuneration of Directors (6) Remuneration of Supervisors (7) General Mandate to Issue Additional Shares (8) Pro